Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faster-acting insulin aspart vs NovoRapid in insulin pump-treated adults with type 1 diabetes
NL-OMON43891Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Faster-acting insulin aspart CSII with NovoRapid CSII (2 arms). Primary endpoint: Change from baseline in HbA1c at 16 weeks after randomization. Started Jul 2016; status: active, not recruiting.
02
Drugs
insulin aspartfaster-acting insulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON43891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43891.